HKD 11.24
(1.81%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | -504.51 Million CNY | -50.58% |
2022 | -388.18 Million CNY | -60.49% |
2021 | -241.87 Million CNY | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q2 | -84.61 Million CNY | 0.0% |
2024 Q1 | -84.61 Million CNY | 45.06% |
2023 Q4 | -154.02 Million CNY | -33.32% |
2023 Q3 | -115.53 Million CNY | 10.37% |
2023 FY | -584.54 Million CNY | -50.58% |
2023 Q2 | -128.89 Million CNY | 0.0% |
2023 Q1 | -128.89 Million CNY | -5.81% |
2022 FY | -388.18 Million CNY | -60.49% |
2022 Q4 | -121.81 Million CNY | 0.0% |
2021 FY | -241.87 Million CNY | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Uni-Bio Science Group Limited | 67.76 Million HKD | 844.469% |
CK Life Sciences Int'l., (Holdings) Inc. | 897.95 Million HKD | 156.185% |